Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration—A Danish Cohort Study
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine patient characteristics and dose titration patterns of real-world semaglutide (Wegovy) users. RESEARCH DESIGN AND METHODS: We used a population-based cohort study including Danish adults who filled semaglutide prescriptions from 12 December 2022 to 31 December 2023. Outcomes were patient characteristics, prescriber type, and dose titration patterns. RESULTS: We identified 110,748 individuals (median age 49 years; 70% female) filling 773,708 prescriptions for semaglutide. General practitioners initiated treatment in 86%. Common comorbidities included hypertension (30%), dyslipidemia (17%), and arthrosis (17%). Only 13% reached the maximum dose of 2.4 mg by their fifth prescription, while 5.7% stopped after the first prescription. Few users (10%) followed recommended dose increases every 4 weeks. Overall, 25% filled at least one prescription of 2.4 mg, while 33–48% continued with the 1.0-mg dosage from the fourth prescription onward. CONCLUSIONS: Real-world semaglutide users generally resembled trial participants, but few follow the dose titration schemes tested in premarket clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a Danish population‐based cohort study of 110 749 initiators of semaglutide for obesity, about 50% persisted for one year. 37”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [37]
In the citing paper
“Real‐world studies demonstrate high discontinuation rates of GLP‐1RAs (20%–50%) within the first year, and the use of much lower doses than those evaluated in clinical trials.”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [37]
In the citing paper
“Notably, only 10% followed the recommended semaglutide dose increases every four weeks, and only 12% reached the recommended target dose of 2.4 mg by their 5th prescription, with one in three users continuing with the low 1.0 mg dose for a prolonged time. 37”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [37]
In the citing paper
“Notably, only 10% followed the recommended semaglutide dose increases every four weeks, and only 12% reached the recommended target dose of 2.4 mg by their 5th prescription, with one in three users continuing with the low 1.0 mg dose for a prolonged time. 37”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [37]
In the citing paper
“Notably, only 10% followed the recommended semaglutide dose increases every four weeks, and only 12% reached the recommended target dose of 2.4 mg by their 5th prescription, with one in three users continuing with the low 1.0 mg dose for a prolonged time. 37”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Data Resource Profile: The Danish National Prescription Registry
Pottegård, A., Schmidt, S. A. J., Wallach-Kildemoes, H., Sørensen, H. T., Hallas, J., & Schmidt, M. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw213 · Cited by 1,431
Self-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Thygesen, L. C., Daasnes, C., Thaulow, I., & Brønnum-Hansen, H. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811399956 · Cited by 1,084
Van Spall, H. G. C., Toren, A., Kiss, A., & Fowler, R. A. (2007) · JAMA · doi:10.1001/jama.297.11.1233 · Cited by 1,055
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814
He, J., Morales, D. R., & Guthrie, B. (2020) · Trials · doi:10.1186/s13063-020-4139-0 · Cited by 147
Population Pharmacokinetics of Semaglutide for Type 2 Diabetes
Overgaard, R. V., Delff, P. H., Petri, K. C. C., Anderson, T. W., Flint, A., & Ingwersen, S. H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0581-y · Cited by 47
Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland
Haase, C. L., Serratore Achenbach, M. G., Lucrezi, G., Jeswani, N., Maurer, S., & Egermann, U. (2021) · Obesity Facts · doi:10.1159/000518325 · Cited by 41
Knudsen, J. S., Thomsen, R. W., Pottegård, A., Knop, F. K., & Sørensen, H. T. (2018) · Diabetes Care · doi:10.2337/dc18-0999 · Cited by 21
Self-citation
Cited by
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Self-citationCagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., Lingvay, I., Lyndgaard, C. B., Rosenstock, J., & Pedersen, S. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502082 · Cited by 143
Noureddin, M., Harrison, S. A., Loomba, R. S., Alkhouri, N., Chalasani, N., Sheikh, M. Y., Tomah, S., Gutierrez, J. A., Urbina, S., Suschak, J. J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02114-2 · Cited by 66
Determinants of adherence to obesity medication: A narrative review
Sharma, A. M., Birney, S., Crotty, M., Finer, N., Segal‐Lieberman, G., Vázquez‐Velázquez, V., & Vrijens, B. (2025) · Obesity Reviews · doi:10.1111/obr.13885 · Cited by 42
“39 Persistence may also be lower in people using OMs compared with medications for the other listed chronic diseases (Table 1).”
Samuels, J. M., Ye, F., Irlmeier, R., Silver, H., Srivastava, G., & Spann, M. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70004 · Cited by 35
“12 Similarly, we found only 22% of our patients received at least one prescription for 2.4 mg semaglutide, although 55% reached 2 mg or higher.”
Influential
Metadata
- Authors
- Ladebo, L., Ernst, M. T., Mailhac, A., Dirksen, C., Bojsen-Møller, K. N., & Pottegård, A.
- Affiliations
- University of Southern Denmark (DK)
- 2Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
- University of Copenhagen (DK)
- Corresponding author
- Ladebo, Louise
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2024-08-06
- Volume
- 47
- Issue
- 10
- Pages
- 1834-1837
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4401362613
- Semantic Scholar
- 2c608147363bef907c9b67b1b269a7ee9fa30a21
- Cited by
- 46
- References
- 14
- Citations by year
- 2026: 22 · 2025: 23 · 2024: 1
- FWCI
- 13.00
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Scopus (Elsevier) (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- Funders
- Aarhus Universitet
- Aarhus Universitetshospital
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- semaglutide, Wegovy, weight management, obesity treatment, dose titration, real-world prescribing patterns, patient characteristics, general practitioners, medication adherence, prescription refills, comorbidities
- MeSH terms
- Semaglutide, Adult, Aged, Denmark, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.